Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

University of Turin, Turin, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:5City/State/Province:Turin
Treatments:Biologic therapyHospital:University of Turin
Drugs:Journal:Link
Date:Nov 2009

Description:

Patients: This phase 2 study involved 47 patients with advanced non-small cell lung cancer. Their median age was 60, ranging from 37 to 81 years of age. There were 27 men and 20 women.

Treatment: Patients were treated with the biological therapy sunitinib.

Toxicity: Seven patients died while on the study. Four died from disease or worsening health, one died of a pulmonary embolism, one from treatment-related congestive heart failure, and one from disease progression and pulmonary embolism.

Results: The median overall survival was 8.5 months (37.1 weeks).

Support: This study was supported by research funds from Pfizer, which markets sunitinib as SUTENT.

Correspondence: Dr. Silvia Novello



Back